Recent developments of pyrimidine appended HIV-1 non-nucleoside reverse transcriptase inhibitors
Bioorganic Chemistry · 2025
DOI: 10.1016/j.bioorg.2025.108273 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von S Maheen Abdul Rahman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, VPO-Ghudda, Bathinda 151401, Punjab, India. Hauptthemen laut MEDLINE: Reverse Transcriptase Inhibitors, Pyrimidines, HIV Reverse Transcriptase, HIV-1. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 150 Literaturangaben. Gefördert von: University of Central Punjab, All India Council for Technical Education.
Abstract (Originalsprache)
Acquired Immune Deficiency Syndrome (AIDS) is an ailment that progressively weakens the immune system and is responsible for being the sole cause of 630,000 deaths worldwide in 2023. It is a potentially fatal condition that promotes the growth of malignancies and secondary infection. Viruses like Human Immunodeficiency Virus (HIV-1) and Hepatitis B virus (HBV) employ an enzyme, reverse transcriptase (RT), to replicate their genomes and spread across the host genome. RT has proved to be one of the most important therapeutic targets for the treatment of AIDS as well as for the development of new HIV-1 medications. The pyrimidine nucleus has been described as a dynamic cornerstone in developing new anti-HIV-1 medications and represents a familiar motif found in various marketed anti-HIV-1 drugs, such as diaryl pyrimidines (DAPYs). The rapid emergence of drug-resistant viral strains due to mutations in the HIV-1 RT structure along with their unfavourable pharmacokinetics present new challenges. Recent years have witnessed tremendous progress in the design and discovery of new substituted pyrimidines as potent and selective non-nucleoside reverse transcriptase inhibitors (NNRTIs). Further, the current developments in the field of X-ray crystallography and molecular modeling have remarkably augmented the design strategies, with simultaneous improvement in the resistance profiles. This article comprehensively reviews recent trends in the design and development of pyrimidine-based HIV-1 NNRTIs. The study emphasizes their biological activities, structure-activity relationship, and docking studies to guide the rational design of NNRTIs with desired potency, safety, and efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, VPO-Ghudda, Bathinda 151401, Punjab, India.
- Department of Pharmaceutical Chemistry, ISF College of Pharmacy, GT Road, Ghal Kalan, Moga 142001, India.
- Department of Pharmaceutical Sciences, Joan M. Lafleur College of Pharmacy and Health Sciences, Texas Southern University, Houston, Texas 77004, USA.
- Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, VPO-Ghudda, Bathinda 151401, Punjab, India. Electronic address: vikramdeep.monga@cup.edu.in.
Förderung
- University of Central Punjab
- All India Council for Technical Education
Zitieren
APA
Rahman, S. M. A., Singh, G., Khan, M. S., Balasubramaniam, A. K., & Monga, V. (2025). Recent developments of pyrimidine appended HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.108273
Vancouver
Rahman SMA, Singh G, Khan MS, Balasubramaniam AK, Monga V. Recent developments of pyrimidine appended HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2025.108273
BibTeX
@article{Rahman2025,
author = {Rahman, S Maheen Abdul and Singh, Gurpreet and Khan, Mhd Shabbu and Balasubramaniam, Arun Kumar and Monga, Vikramdeep},
title = {Recent developments of pyrimidine appended HIV-1 non-nucleoside reverse transcriptase inhibitors},
journal = {Bioorganic Chemistry},
year = {2025},
doi = {10.1016/j.bioorg.2025.108273}
}
EUVIMED